Spots Global Cancer Trial Database for romidepsin
Every month we try and update this database with for romidepsin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00062075 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
| A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | NCT02512172 | Colorectal Canc... | Oral CC-486 Romidepsin MK-3475 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | NCT02616965 | Cutaneous T-cel... | Romidepsin Brentuximab ved... | 18 Years - | Fox Chase Cancer Center | |
| Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | NCT02061449 | Cutaneous T-cel... | Romidepsin Poly ICLC Focal lesional ... | 18 Years - | NYU Langone Health | |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | NCT03534180 | Anaplastic Larg... Recurrent Matur... Refractory Matu... | Laboratory Biom... Romidepsin Venetoclax | 18 Years - | City of Hope Medical Center | |
| A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) | NCT01456039 | Lymphoma, T-cel... | Romidepsin | 20 Years - | Celgene | |
| Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients | NCT01822886 | Peripheral T-ce... | Romidepsin + Ge... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Long-term Use of Romidepsin in Patients With CTCL | NCT02296398 | Cutaneous T-cel... | Romidepsin | 18 Years - 89 Years | Northwestern University | |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | NCT01938833 | HER2-negative B... Inflammatory Br... Male Breast Can... Recurrent Breas... Stage IV Breast... | Romidepsin Abraxane | 18 Years - | Thomas Jefferson University | |
| FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00383565 | Recurrent Adult... Recurrent Mantl... | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) | NCT01456039 | Lymphoma, T-cel... | Romidepsin | 20 Years - | Celgene | |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324323 | Hematologic Mal... Malignant Lymph... | Romidepsin Rifampin | 18 Years - | Celgene | |
| A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) | NCT01456039 | Lymphoma, T-cel... | Romidepsin | 20 Years - | Celgene | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma | NCT01846390 | Peripheral T-Ce... Diffuse Large B... | Gemcitabine Dexamethasone Cisplatin Romidepsin | 18 Years - | Canadian Cancer Trials Group | |
| Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | NCT04233697 | Lymphoma, T-Cel... | Copanlisib Romidepsin | 18 Years - | Columbia University | |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | NCT02281279 | B-cell Adult Ac... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac... | rituximab lenalidomide romidepsin laboratory biom... | 18 Years - | Mayo Clinic | |
| FR901228 in Treating Patients With Metastatic Breast Cancer | NCT00098397 | Male Breast Can... Recurrent Breas... Stage IV Breast... | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | NCT04257448 | Pancreas Cancer Pancreatic Aden... Pancreatic Duct... | Romidepsin Azacitidine nab-Paclitaxel Gemcitabine Durvalumab Lenalidomide ca... | 18 Years - | GWT-TUD GmbH | |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | NCT04257448 | Pancreas Cancer Pancreatic Aden... Pancreatic Duct... | Romidepsin Azacitidine nab-Paclitaxel Gemcitabine Durvalumab Lenalidomide ca... | 18 Years - | GWT-TUD GmbH | |
| A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | NCT02512172 | Colorectal Canc... | Oral CC-486 Romidepsin MK-3475 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | NCT03278782 | Recurrent Anapl... Recurrent Angio... Recurrent Matur... Recurrent Mycos... Recurrent Prima... Refractory Anap... Refractory Angi... Refractory Matu... Refractory Myco... Refractory Peri... Refractory Prim... | Pembrolizumab Romidepsin | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors | NCT00379639 | Pancreatic Canc... | Romidepsin Gemcitabine | 18 Years - | Celgene | |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT01590732 | Mycosis Fungoid... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Hepat... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Hepa... Refractory Peri... | Carboplatin Etoposide Ifosfamide Romidepsin | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors | NCT00379639 | Pancreatic Canc... | Romidepsin Gemcitabine | 18 Years - | Celgene | |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | NCT04774068 | Recurrent Anapl... Recurrent Matur... Recurrent Prima... Recurrent Trans... Refractory Anap... Refractory Matu... Refractory Prim... Refractory Tran... T-Cell Non-Hodg... | Parsaclisib Romidepsin | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00066638 | DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Romidepsin Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | NCT02512172 | Colorectal Canc... | Oral CC-486 Romidepsin MK-3475 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | NCT02181218 | Lymphoma, T-Cel... Lymphoma, T-Cel... Hodgkin Disease Lymphoma, Large... | Romidepsin Gemcitabine Oxaliplatin Dexamethasone Pegfilgrastim | 18 Years - | Washington University School of Medicine | |
| FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | NCT00079443 | Recurrent Grade... Recurrent Grade... Recurrent Small... | romidepsin rituximab fludarabine pho... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT00084682 | Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | NCT00079443 | Recurrent Grade... Recurrent Grade... Recurrent Small... | romidepsin rituximab fludarabine pho... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma | NCT01846390 | Peripheral T-Ce... Diffuse Large B... | Gemcitabine Dexamethasone Cisplatin Romidepsin | 18 Years - | Canadian Cancer Trials Group | |
| Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | NCT03547700 | Lymphoma, T-Cel... | Romidepsin Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors | NCT00379639 | Pancreatic Canc... | Romidepsin Gemcitabine | 18 Years - | Celgene | |
| FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00077194 | Lymphoma | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | NCT00007345 | Cutaneous T Cel... Peripheral T Ce... | Romidepsin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma | NCT03703375 | Lymphoma, T-Cel... | Azacitidine Romidepsin Gemcitabine | 18 Years - | Celgene | |
| FR901228 in Treating Patients With Metastatic Breast Cancer | NCT00098397 | Male Breast Can... Recurrent Breas... Stage IV Breast... | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL | NCT03593018 | Relapsed Angioi... Refractory Angi... | Oral azacitidin... Romidepsin Bendamustine Gemcitabine | 18 Years - | The Lymphoma Academic Research Organisation | |
| Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer | NCT00086827 | Recurrent Small... | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | NCT02061449 | Cutaneous T-cel... | Romidepsin Poly ICLC Focal lesional ... | 18 Years - | NYU Langone Health | |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | NCT03355768 | Lymphoma, T-Cel... | Romidepsin Pralatrexate | 18 Years - 90 Years | Columbia University | |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | NCT03534180 | Anaplastic Larg... Recurrent Matur... Refractory Matu... | Laboratory Biom... Romidepsin Venetoclax | 18 Years - | City of Hope Medical Center | |
| Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | NCT01755975 | Multiple Myelom... Non-Hodgkin's L... | Romidepsin Lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients | NCT03141203 | Peripheral T Ce... | Romidepsin Carfilzomib | 16 Years - | University of Birmingham | |
| FR901228 in Treating Patients With Hematologic Cancer | NCT00024180 | Leukemia Lymphoma | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | NCT02393794 | Triple-Negative... Breast Cancer | Romidepsin Cisplatin Nivolumab | 18 Years - | University of Kansas Medical Center | |
| FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer | NCT00098527 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Esoph... Recurrent Gastr... | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma | NCT01979276 | Multiple Myelom... | Romidepsin pomalidomide Dexamethasone | 18 Years - 100 Years | Weill Medical College of Cornell University | |
| A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | NCT02512172 | Colorectal Canc... | Oral CC-486 Romidepsin MK-3475 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Trial of Romidepsin and Bortezomib for Multiple Myeloma | NCT00765102 | Multiple Myelom... | Bortezomib Romidepsin | 18 Years - | Celgene | |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | NCT01897012 | MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu... | Alisertib Laboratory Biom... Romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | NCT02181218 | Lymphoma, T-Cel... Lymphoma, T-Cel... Hodgkin Disease Lymphoma, Large... | Romidepsin Gemcitabine Oxaliplatin Dexamethasone Pegfilgrastim | 18 Years - | Washington University School of Medicine | |
| Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma | NCT03703375 | Lymphoma, T-Cel... | Azacitidine Romidepsin Gemcitabine | 18 Years - | Celgene | |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | NCT03534180 | Anaplastic Larg... Recurrent Matur... Refractory Matu... | Laboratory Biom... Romidepsin Venetoclax | 18 Years - | City of Hope Medical Center | |
| Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients | NCT01822886 | Peripheral T-ce... | Romidepsin + Ge... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | NCT03161223 | Lymphoma, T-Cel... | Durvalumab Pralatrexate Romidepsin 5-Azacitidine | 18 Years - | University of Virginia | |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | NCT00084461 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Regional Gastro... Somatostatinoma | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | NCT01482962 | Relapsed Periph... Refractory Peri... | Alisertib Pralatrexate Gemcitabine Romidepsin | 18 Years - | Takeda | |
| A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | NCT00106431 | Cutaneous T-cel... | romidepsin (dep... | 18 Years - | Celgene | |
| Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324310 | Hematologic Mal... Malignant Lymph... | Romidepsin Ketoconazole | 18 Years - | Celgene | |
| Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00062075 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | NCT01998035 | Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Romidepsin Oral 5-Azacitid... | 18 Years - | Columbia University | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| Long-term Use of Romidepsin in Patients With CTCL | NCT02296398 | Cutaneous T-cel... | Romidepsin | 18 Years - 89 Years | Northwestern University | |
| Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | NCT01755975 | Multiple Myelom... Non-Hodgkin's L... | Romidepsin Lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | NCT03770000 | T Cell Lymphoma | Tenalisib Romidepsin | 18 Years - | Rhizen Pharmaceuticals SA | |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | NCT01998035 | Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Romidepsin Oral 5-Azacitid... | 18 Years - | Columbia University | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | NCT00084461 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Regional Gastro... Somatostatinoma | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00066638 | DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Romidepsin Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | NCT01938833 | HER2-negative B... Inflammatory Br... Male Breast Can... Recurrent Breas... Stage IV Breast... | Romidepsin Abraxane | 18 Years - | Thomas Jefferson University | |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | NCT03161223 | Lymphoma, T-Cel... | Durvalumab Pralatrexate Romidepsin 5-Azacitidine | 18 Years - | University of Virginia | |
| FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer | NCT00077337 | Colorectal Canc... | romidepsin | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
